{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:52:54Z","timestamp":1790880774774,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jpba.2023.115538","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T02:13:44Z","timestamp":1687227224000},"page":"115538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Successful LC-MS\/MS assay development and validation for determination of valproic acid and its metabolites supporting proactive pharmacovigilance"],"prefix":"10.1016","volume":"234","author":[{"given":"Wei-Jun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Tao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2084-0862","authenticated-orcid":false,"given":"Hao-Ran","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Li","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan-Sheng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jpba.2023.115538_bib1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jhep.2021.10.011","article-title":"Long-term sequelae of drug-induced liver injury","volume":"76","author":"Bj\u00f6rnsson","year":"2022","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.jpba.2023.115538_bib2","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jhep.2021.12.013","article-title":"Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study","volume":"76","author":"Chalasani","year":"2022","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.jpba.2023.115538_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2174\/1381612825666190329145428","article-title":"Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update","volume":"25","author":"Guo","year":"2019","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.jpba.2023.115538_bib4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1528-1157.1993.tb02419.x","article-title":"Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity","volume":"34","author":"Siemes","year":"1993","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.jpba.2023.115538_bib5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharm. Genom."},{"issue":"2","key":"10.1016\/j.jpba.2023.115538_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","article-title":"Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review","volume":"31","author":"Silva","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"issue":"10","key":"10.1016\/j.jpba.2023.115538_bib7","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00228-012-1277-7","article-title":"Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients","volume":"68","author":"Chu","year":"2012","journal-title":"Eur. J. Clin. Pharm."},{"issue":"11","key":"10.1016\/j.jpba.2023.115538_bib8","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00228-015-1925-9","article-title":"Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7\u2013161\u2009C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children","volume":"71","author":"Liu","year":"2015","journal-title":"Eur. J. Clin. Pharm."},{"issue":"8","key":"10.1016\/j.jpba.2023.115538_bib9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00228-018-2440-6","article-title":"Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model","volume":"74","author":"Mei","year":"2018","journal-title":"Eur. J. Clin. Pharm."},{"issue":"11","key":"10.1016\/j.jpba.2023.115538_bib10","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1124\/dmd.114.059352","article-title":"Evaluation of in situ generated valproyl 1-O-\u03b2-acyl glucuronide in valproic acid toxicity in sandwich-cultured rat hepatocytes","volume":"42","author":"Surendradoss","year":"2014","journal-title":"Drug Metab. Dispos.: Biol. Fate Chem."},{"issue":"5","key":"10.1016\/j.jpba.2023.115538_bib11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2125.2000.00191.x","article-title":"Apparent autoinduction of valproate beta-oxidation in humans","volume":"49","author":"McLaughlin","year":"2000","journal-title":"Br. J. Clin. Pharm."},{"issue":"3","key":"10.1016\/j.jpba.2023.115538_bib12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.taap.2012.08.018","article-title":"Assessment of the role of in situ generated (E)-2,4-diene-valproic acid in the toxicity of valproic acid and (E)-2-ene-valproic acid in sandwich-cultured rat hepatocytes","volume":"264","author":"Surendradoss","year":"2012","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.jpba.2023.115538_bib13","doi-asserted-by":"crossref","unstructured":"N.A. Shnayder, V.V. Grechkina, A.K. Khasanova, E.N. Bochanova, E.A. Dontceva, M.M. Petrova, A.R. Asadullin, G.A. Shipulin, K.S. Altynbekov, M. Al-Zamil, R.F. Nasyrova, Therapeutic and Toxic Effects of Valproic Acid Metabolites, Metabolites 13 1 2023.","DOI":"10.3390\/metabo13010134"},{"issue":"3","key":"10.1016\/j.jpba.2023.115538_bib14","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10545-011-9423-4","article-title":"Inhibition of 3-methylcrotonyl-CoA carboxylase explains the increased excretion of 3-hydroxyisovaleric acid in valproate-treated patients","volume":"35","author":"Luis","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4791","key":"10.1016\/j.jpba.2023.115538_bib15","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1126\/science.3101178","article-title":"Cytochrome P-450--catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid","volume":"235","author":"Rettie","year":"1987","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jpba.2023.115538_bib16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/toxsci\/kfl096","article-title":"Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1\/*1 genotype","volume":"94","author":"Kiang","year":"2006","journal-title":"Toxicol. Sci."},{"issue":"6","key":"10.1016\/j.jpba.2023.115538_bib17","first-page":"335","article-title":"Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes","volume":"3","author":"Ho","year":"2003","journal-title":"Pharm. J."},{"key":"10.1016\/j.jpba.2023.115538_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.etap.2022.103967","article-title":"Valproic acid induced liver injury: an insight into molecular toxicological mechanism","volume":"95","author":"Ezhilarasan","year":"2022","journal-title":"Environ. Toxicol. Pharmacol."},{"issue":"8\u20139","key":"10.1016\/j.jpba.2023.115538_bib19","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3109\/00498258509047438","article-title":"Inhibition of gluconeogenesis by sodium valproate and its metabolites in isolated rat hepatocytes","author":"Rogiers","year":"1985","journal-title":"Xenobiotica"},{"issue":"11","key":"10.1016\/j.jpba.2023.115538_bib20","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1016\/0006-2952(92)90324-C","article-title":"In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance of CoA sequestration to the observed inhibitions","volume":"43","author":"Ponchaut","year":"1992","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jpba.2023.115538_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.750744","article-title":"Switching between LC-ESI-MS\/MS and EMIT methods for routine TDM of valproic acid in pediatric patients with epilepsy: what clinicians and researchers need to know","volume":"12","author":"Xia","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.jpba.2023.115538_bib22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.seizure.2011.10.002","article-title":"Simultaneous determination of valproic acid and 2-propyl-4-pentenoic acid for the prediction of clinical adverse effects in Chinese patients with epilepsy","volume":"21","author":"Chen","year":"2012","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.jpba.2023.115538_bib23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0378-4347(94)00129-4","article-title":"Sensitive capillary gas chromatographic-mass spectrometric method for the therapeutic drug monitoring of valproic acid and seven of its metabolites in human serum. Application of the assay for a group of pediatric epileptics","volume":"656","author":"Darius","year":"1994","journal-title":"J. Chromatogr. B Biomed. Appl."},{"issue":"1","key":"10.1016\/j.jpba.2023.115538_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1528-1157.1992.tb02301.x","article-title":"Valproate metabolites in serum and urine during antiepileptic therapy in children with infantile spasms: abnormal metabolite pattern associated with reversible hepatotoxicity","volume":"33","author":"Fisher","year":"1992","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.jpba.2023.115538_bib25","first-page":"436","article-title":"Simultaneous determination of valproic acid and its major metabolites by UHPLC-MS\/MS in Chinese patients: application to therapeutic drug monitoring","volume":"55","author":"Zhao","year":"2017","journal-title":"J. Chromatogr. Sci."},{"issue":"21","key":"10.1016\/j.jpba.2023.115538_bib26","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.jchromb.2011.05.022","article-title":"LC-MS\/MS method for simultaneous determination of valproic acid and major metabolites in human plasma","volume":"879","author":"Gao","year":"2011","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2023.115538_bib27","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jpba.2017.11.042","article-title":"A rapid and simple HPLC-MS\/MS method for the simultaneous quantification of valproic acid and its five metabolites in human plasma and application to study pharmacokinetic interaction in Chinese epilepsy patients","volume":"149","author":"Wen","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1\u20132","key":"10.1016\/j.jpba.2023.115538_bib28","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jchromb.2006.11.027","article-title":"Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS\/MS","author":"Cheng","year":"2007","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 850("},{"issue":"6","key":"10.1016\/j.jpba.2023.115538_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10061153","article-title":"Valproic acid-induced liver injury: a case-control study from a prospective pharmacovigilance program in a tertiary hospital","volume":"10","author":"Meseguer","year":"2021","journal-title":"J. Clin. Med"},{"issue":"7","key":"10.1016\/j.jpba.2023.115538_bib30","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s12272-009-1708-x","article-title":"The relationship between glucuronide conjugate levels and hepatotoxicity after oral administration of valproic acid","volume":"32","author":"Lee","year":"2009","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.jpba.2023.115538_bib31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.tox.2015.03.001","article-title":"Sodium valproate induces mitochondrial respiration dysfunction in HepG2 in vitro cell model","volume":"331","author":"Komulainen","year":"2015","journal-title":"Toxicology"},{"issue":"3","key":"10.1016\/j.jpba.2023.115538_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5572","article-title":"Determination of valproic acid and its six metabolites in human serum using LC-MS\/MS and application to interaction with carbapenems in epileptic patients","volume":"37","author":"Yang","year":"2023","journal-title":"Biomed. Chromatogr.: BMC"},{"issue":"14","key":"10.1016\/j.jpba.2023.115538_bib33","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.4155\/bio-2017-0059","article-title":"Matrix effect management in liquid chromatography mass spectrometry: the internal standard normalized matrix effect","volume":"9","author":"De Nicol\u00f2","year":"2017","journal-title":"Bioanalysis"},{"issue":"5","key":"10.1016\/j.jpba.2023.115538_bib34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4155\/bio-2016-0157","article-title":"Simultaneous assay of multiple antibiotics in human plasma by LC-MS\/MS: importance of optimizing formic acid concentration","volume":"9","author":"Chen","year":"2017","journal-title":"Bioanalysis"},{"issue":"3","key":"10.1016\/j.jpba.2023.115538_bib35","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/jms.2050","article-title":"Nebulizing conditions of pneumatic electrospray ionization significantly influence electrolyte effects on compound measurement","volume":"47","author":"Niu","year":"2012","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.jpba.2023.115538_bib36","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jpba.2012.08.029","volume":"72","author":"Hu","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"9","key":"10.1016\/j.jpba.2023.115538_bib37","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.2174\/138920012803341320","article-title":"Strategies for improving the quantitative bioanalytical performance of LC-MS in pharmacokinetic studies","volume":"13","author":"Li","year":"2012","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jpba.2023.115538_bib38","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.12659\/MSM.897626","article-title":"Association of UGT2B7 and UGT1A4 polymorphisms with serum concentration of antiepileptic drugs in children","volume":"22","author":"Du","year":"2016","journal-title":"Med. Sci. Monit.: Int. Med. J. Exp. Clin. Res."},{"key":"10.1016\/j.jpba.2023.115538_bib39","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.seizure.2018.04.012","article-title":"Determinants of free serum valproate concentration: a prospective study in patients on divalproex sodium monotherapy","volume":"59","author":"Nasreddine","year":"2018","journal-title":"Seizure"},{"issue":"5","key":"10.1016\/j.jpba.2023.115538_bib40","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/FTD.0000000000000751","article-title":"Impact of age and genotype on serum concentrations of valproic acid and its hepatotoxic metabolites in chinese pediatric patients with epilepsy","volume":"42","author":"Zhao","year":"2020","journal-title":"Ther. Drug Monit."},{"issue":"6","key":"10.1016\/j.jpba.2023.115538_bib41","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1528-1157.1978.tb05039.x","article-title":"Identification of metabolites of valproic acid in serum of humans, dog, rat, and mouse","volume":"19","author":"Jakobs","year":"1978","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.jpba.2023.115538_bib42","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0891-5849(03)00151-5","article-title":"The effect of valproic acid on hepatic and plasma levels of 15-F2t-isoprostane in rats","volume":"34","author":"Tong","year":"2003","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.jpba.2023.115538_bib43","article-title":"Determination of valproic acid and its six metabolites in human serum using LC-MS\/MS and application to interaction with carbapenems in epileptic patients","author":"Yang","year":"2022","journal-title":"Biomed. Chromatogr."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523003072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523003072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:31:01Z","timestamp":1760002261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523003072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":43,"alternative-id":["S0731708523003072"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115538","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful LC-MS\/MS assay development and validation for determination of valproic acid and its metabolites supporting proactive pharmacovigilance","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115538","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115538"}}